Используйте голову, чтобы спасти мозг. Профилактика деменции в любом возрасте
Шрифт:
Особое спасибо Джо Раско за его превосходную поддержку и Терри Ли Полсену, методически вычитавшему каждое слово. Благодарим также наших старинных друзей, Кейти Алмонд Якобс, автора трех книг, и Джерри Доктороу, за их советы и помощь в нужных контактах.
Мы надеемся написать следующую книгу в содружестве с медицинскими организациями, занятыми профилактикой деменции и ее лечением у тех, кому уже поставили этот диагноз. Но и это не все: будет следующая книга, и не одна. Кто знает? Иногда новое оказывается легче, когда ты начинаешь
Библиография
Ehrlich JR, Goldstein J, Swenor BK, Whitson H, Langa KM, Veliz P. Addition of vision impairment to a life-course model of potentially modifiable dementia risk factors in the US. JAMA Neurol. 2022 Jun 1;79(6):623–626. doi: 10.1001 /jamaneurol.2022.0723. Erratum in: JAMA Neurol. 2022 Jun 1;79(6):634.
PMID: 35467745; PMCID: PMC9039828.
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–446. doi: 10.1016/S0140-6736(20)30367–6. Epub 2020 Jul 30.
Mace NL, Rabins PV. The 36-hour day: a family guide to caring for people who have Alzheimer disease and other dementia. 7th ed. Johns Hopkins University Press; 2021.
Royal Society for Public Health. That age old question: how attitudes to ageing affect our health and wellbeing.Last accessed July 2, 2022.
Zissimopoulos J, Jacobson M, Chen Y, Borson S. Knowledge and attitudes concerning Aducanumab among older Americans after FDA approval for treatment of Alzheimer disease. JAMA Netw Open. 2022;5(2):e2148355.
doi: 10.1001/jamanetworkopen.2021.48355
Ahmed RM, Paterson RW, Warren JD, et al. Biomarkers in dementia: clinical utility and new directions. J Neurol Neurosurg Psychiatry. 2014;85(12):1426–1434. doi: 10.1136/jnnp.2014.307662 218 For Further Reading
Amaducci LA, Rocca WA, Schoenberg BS. Origin of the distinction between Alzheimer’s disease and senile dementia: how history can clarify nosology. Neurology. 1986;36(11): 1497–1499. doi: 10.1212/wnl.36.11.1497
Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. J Am Med Assoc. 2019;322(16):1589–1599. doi: 10.1001/jama.2019.4782
Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203–212. doi: 10.1097/00002093-200210000-00001
Benjamin S, MacGillivray L, Schildkrout B, Cohen-Oram A, Lauterbach MD, Levin LL. Six landmark case reports essential for neuropsychiatric literacy. J Neuropsychiatry Clin Neurosci. 2018;30(4):279–290. doi: 10.1176/appi.neuro psych.18020027. Epub 2018 Aug 24.
Blazer DG, Yaffe K, Liverman C, eds. Cognitive aging: progress in understanding and opportunities for action. National Academies Press; 2015. doi: 10.17226/21693
Boyle PA, Yu L, Wilson RS, Schneider JA, Bennett DA. Relation of neuropathology with cognitive decline among older persons without dementia. Front Aging Neurosci. 2013;9(5):50. doi: 10.3389/fnagi.2013.00050
Clionsky M, Clionsky E. Identifying cognitive impairment in the annual wellness visit: who can you trust? J Fam Pract, 2011;60(11):653–659.
Dang, C, Maruff, P. SuperAging: current findings yield future challenge: A response to Rogalski and Goldberg. Alzheimers Dement (Amst). 2019;11:562–563. doi: 10.1016/j.dadm.2019.05.004
DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14(32). doi: 10.1186/s13024-019-0333-5
Drachman DA. The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer’s disease. Alzheimers Dement. 2014 May;10(3):372–380. doi: 10.1016/j.jalz.2013.11.003
Dubois B, Hampel H, Feldman HH, et al. Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer’s Association on “The preclinical state of AD”; July 23, 2015; Washington DC, USA. Preclinical
Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292–323. doi: 10.1016/j.jalz.2016.02.002
Elahi F, Miller B. A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol. 2017 Aug;13(8):457–476. doi: 10.1038/nrneurol.2017.96
Fox N, Petersen R. The G8 Dementia Research Summit – a starter for eight? Lancet. 2013;382(9909):1968–1969. doi: 10.1016/S0140-6736(13)62426–5
Goodman RA, Lochner KA, Thambisetty M, Wingo TS, Posner SF, Ling SM. Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011–2013. Alzheimers Dement. 2017 Jan;13(1):28–37. doi: 10.1016/ j.jalz.2016.04.002. Epub 2016 May 10.
Graff-Radford J. Vascular cognitive impairment. Continuum. 2019 Feb;25(1):147–164. doi: 10.1212/CON.0000000000000684
Hale JM, Schneider DC, Mehta NK, Myrskyla M. Cognitive impairment in the U.S.: lifetime risk, age at onset, and years impaired. SSM Popul Health. 2020;11:100577. doi: 10.1016/j.ssmph.2020.100577. Erratum in: SSM Popul Health. 2020 Dec 10;12:100715.
Imtiaz B, Tolppanen AM, Kivipelto M, Soininen H. Future directions in Alzheimer’s disease from risk factors to prevention. Biochem Pharmacol. 2014;88(4):661–670. doi: 10.1016/j.bcp.2014.01.003. Epub 2014 Jan 10.
Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134(2):171–186. doi: 10.1007/s00401-017-1717-7. Epub 2017 May 9.